LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC) Meeting Abstract
| Authors: | Dent, R. A.; Kim, S. B.; Im, S. A.; Espie, M.; Blau, S.; Tan, A. R.; Isakoff, S.; Oliveira, M.; Saura, C.; Wongchenko, M.; Kapp, A. V.; Chan, W. Y.; Singel, S. M.; Maslyar, D. J.; Baselga, J. |
| Abstract Title: | LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC) |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 34s |
| Language: | English |
| ACCESSION: | WOS:000411895701146 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.1009 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1009 -- Source: Wos |
